RNA sequensing data of a phase 2 clinical trial of pancreatic ductal adenocarcinoma treated with entinostat in combination with nivolumab

We conducted a single-center, open-label, Simon two-stage, phase II study of entinostat in combination with the PD1 inhibitor nivolumab in patients with advanced pancreatic ductal adenocarcinoma. Patients received oral entinostat 5 mg once a week. After a 14-day lead-in with entinostat monotherapy, patients concurrently receive entinostat 5 mg orally once a week plus nivolumab 240 mg intravenously until the time of progression or unacceptable toxicities. All patients underwent fresh tumor biopsy (subsequent passes flash frozen, formalin-fixed paraffin-embedded, and preserved in RNAlater) at baseline, after two weeks of entinostat lead-in therapy (C1D1), and on week 6 following entinostat given with nivolumab combination therapy (C2D1). The patient data and raw sequencing files are submitted to dbGaP: https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003615.v1.p1.